Sanofi (SNY) Receives Consensus Rating of “Hold” from Analysts
Sanofi (NYSE:SNY) has been assigned a consensus rating of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $53.50.
Several equities research analysts have commented on SNY shares. Argus reiterated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Finally, Cowen and Company restated a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st.
Shares of Sanofi (NYSE SNY) traded up 0.46% during trading on Wednesday, reaching $50.03. The company’s stock had a trading volume of 400,882 shares. The stock’s 50 day moving average price is $49.04 and its 200-day moving average price is $47.90. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.65. The firm has a market cap of $125.65 billion, a PE ratio of 11.62 and a beta of 0.87.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts predict that Sanofi will post $3.33 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/sanofi-sny-receives-consensus-rating-of-hold-from-analysts.html.
In related news, major shareholder Sanofi purchased 105,820 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was bought at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Harbour Capital Advisors LLC purchased a new position in Sanofi in the 1st quarter valued at approximately $113,000. Parallel Advisors LLC grew its stake in Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after buying an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC grew its stake in Sanofi by 33.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after buying an additional 776 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after buying an additional 2,098 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in Sanofi by 6,188.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares in the last quarter. Institutional investors and hedge funds own 9.33% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.